Bemnifosbuvir
Bemnifosbuvir (AT-527, RO7496998) is an antiviral drug invented by Atea Pharmaceuticals and licensed to Roche for clinical development, a novel nucleotide analog prodrug originally developed for the treatment of hepatitis C. AT-527 is the orally bioavailable hemisulfate salt of AT-511, which is metabolised in several steps to the active nucleotide triphosphate AT-9010, acting as an RNA polymerase inhibitor and thereby interfering with viral replication. AT-527 has been researched for the treatment of coronavirus diseases such as that produced by SARS-CoV-2. It showed good results in early clinical trials but had inconsistent results at later stages, so the planned Phase 3 trials are being redesigned and results are not expected until late 2022. See also * Galidesivir * Remdesivir * Lufotrelvir * Molnupiravir * Sofosbuvir Sofosbuvir, sold under the brand name Sovaldi among others, is a medication used to treat hepatitis C. It is taken Oral administration, by mouth. Common ...
[...More Info...]       [...Related Items...]     OR:     [Wikipedia]   [Google]   [Baidu]